Patients with acute myeloid leukemia (AML) over the age of 60 have a poor outcome after conventional chemotherapy with only 10-20% becoming long-term survivors. 1 Thanks to the introduction of a variety of reduced-intensity conditioning (RIC) regimens in the late 1990s, more elderly patients have proceeded to allogeneic hematopoietic cell transplantation (HCT). The available data suggest that 30-40% of patients transplanted in first complete remission (CR1) can be cured. 2, 3 RIC has reduced the non-relapse mortality (NRM) compared with myeloablative condition but is often associated with an increased relapse rate. 4 One promising RIC regimen is the FBM protocol which combines carmustine and melphalan with fludarabine. This approach was pioneered by the Freiburg group 5, 6 and subsequently used by the Mayo Clinic. 7 Both groups highlighted low toxicity and high cytoreductive potency especially in advanced disease. In the most recent publication of the Freiburg group, 68% of the 250 reported AML and MDS patients were pretreated prior to transplant and for 32% of patients the FBM conditioning regimen was the primary treatment. 8 A striking finding was that tumor load at the time of transplant did not impact on outcome, which is in contrast to previous publications. 9 In the present study, 53 patients ⩾ 55 years and 4 comorbid patients o55 years of age (n total = 57) diagnosed with AML (de novo AML n = 45, secondary AML n = 7, and therapy-related AML n = 5) at the University Hospital Ulm and the Municipal Hospital of Karlsruhe, who received FBM followed by allogeneic HCT between 2009 and 2015 were included in this analysis. The median age of the group was 64 years. Fifty six out of 57 patients received at least one cycle of induction or salvage chemotherapy before starting the conditioning chemotherapy and 25 patients were treated within a study protocol of the German-Austrian AML study group (AMLSG). All patients gave written informed consent to be treated with this conditioning protocol and to prospective data collection. Relevant patient characteristics and transplant characteristics are included in Table 1 . All patients received the FBM protocol consisting of fludarabine 5 × 30 mg/m 2 from days − 9 to − 5, BCNU 2 × 150 mg/m 2 from days − 7 to − 6, and melphalan 110 mg/m 2 on day − 4. 5 GvHD prophylaxis consisted of tacrolimus (n = 29) or ciclosporine (n = 28) starting on day − 1 prior to transplant plus mycophenolate mofetil (MMF) 720 mg orally or 1000 to 1500 mg IV twice a day starting on the day of transplant. MMF was tapered from day 30 and tacrolimus or ciclosporine from day 100 after transplantation in the absence of GvHD. In addition, all patients with unrelated donor and two patients with MRD received rabbit-ATG (ATG-F, Fresenius) 10 mg/kg or 20 mg/kg for 3 days (n = 39) or alemtuzumab 20 mg total dose (n = 10) prior to transplantation. Statistical analyses evaluating relapse-free survival (RFS), overall survival (OS) by Kaplan-Meier analysis as well as cumulative incidence of relapse (CIR) and death (CID) as competing risk analysis were performed with the R software package using the EZR Module 1.30. Abbreviations: aGvHD = acute GvHD; cGvHD = chronic GvHD; ELN = European Leukemia Network; MRD = matched related donor; MMUD = mismatched unrelated donor; MUD = matched unrelated donor; PBSCT = peripheral blood stem cells.
The median follow-up at the time of analysis was 2.5 years. Most patients were transplanted in CR1 (n = 32) or CR2 (n = 8), 17 refractory patients were transplanted with active disease. Median blast count in the refractory patients in the last marrow evaluation before transplant was 39% (range: 6-90%). Molecular (NPM1, FLT3, CEBPA mutation status) and cytogenetic characteristics were available for all patients.
Overall toxicity of the preparative regimen was low, with a day 30 mortality of 0% and a day 100 mortality of 10.6% (95% CI: 5-22), Only one case of severe toxicity (Bearman Score 3 and 4) occurred. The use of BCNU did not lead to significant pulmonary toxicity 12 months after transplantation compared to the baseline values for FEV 1 (P = 0.61). The median number of infused CD34+ cells was 6.8 × 10 6 (range 0.9-14.9 × 10 6 ) per kg recipient body weight. All patients engrafted. Median time for reconstitution of granulopoiesis (40.5 × 10 9 /L granulocytes) was 17 days (11-99 days) and of thrombopoiesis (450 × 10 9 /L platelets) was 30 days (9-206 days). All patients achieved or maintained a hematological CR on day 30 after transplant with a complete donor chimerism in 54 out of 57 patients measured by STR-PCR.
The cumulative incidence of acute GvHD (aGvHD) grades II (n = 17) to IV (n = 1) at d100 was 33% (95% CI: 19-45%). No patients suffered from grade III aGVHD. The median onset of aGvHD was 32 days (range: 15-95 days). Organs affected were skin (7/18), gastrointestinal tract (18/18) and liver (1/18). The cumulative incidence of chronic GvHD (cGVHD) was 36% (95% CI: 18-49%), at 1 year and 52% (95% CI: 30-67%) at 3 years.
The occurrence of GvHD was not influenced by donor type (P = 0.71 for aGvHD and P = 0.15 for cGvHD). The 1-, 3-and 5-year OS was 73% (95% CI: 59-83%), 53% (95% CI: 38-67%) and 44% (95% CI: 24-63%), respectively ( Figure 1a) . RFS at 1, 3 and 5 years was 65% (95% CI: 51-76%), 49% (95% CI: 34-63%), and 43% (95% CI: 26-59%), respectively (Figure 1b) , which is in line with the published data. 8 However, we observed a significant difference in OS depending on remission status at transplant. When grafted in remission, the 3-year OS was 65% (95% CI: 44-80%), compared to 24% (95% CI: 7-47%) in patients with active disease (P = 0.0003; Figure 1c ). CID at 1, 3 and 5 years was 16% (95% CI: 8-28%), 28% (95% CI: 15-43%), 28% (95% CI: 15-43%) and CIR at 1, 3 and 5 years was 18% (95% CI: 9-30%), 22% (95% CI: 12-35%) and 29% (95% CI: 14-45%), respectively. All relapsed patients, except for three patients with early relapse were treated based on individualized treatment strategies (Supplementary Table 1 ELN classification did not impact on OS (P = 0.35) or RFS (P = 0.38). In addition, no difference in OS was observed for AML patients with either mutated NPM1 (P = 0.19) as compared to NPM1 wildtype or FLT3-ITD (P = 0.40) as compared to patients with no FLT3-ITD. Further clinical factors such as donor type, age, CMV status as well as GvHD did not influence OS, CID or CIR in our cohort. Our data confirm previous reports with respect to toxicity and potency of the FBM protocol. 5, 8 The regimen-related toxicity as measured by Bearman Score was very low without any early deaths and all patients achieved or maintained a CR at day +30. The 3-year OS of 65% of patients grafted in CR is highly encouraging and similar to that reported for patients under the age of 60 years in multiple studies. 12, 13 In contrast to other studies, 12 cytogenetics and molecular markers did not impact on outcome, however, due to the small cohort size this needs to be interpreted with caution. Compared to the Freiburg experience the outcome of patients with active disease at the time of transplant was poor with an OS of 24% after 3 years. Our results are very similar to the Mayo experience where outcome in AML patients correlated with tumor load at the time of transplant, although patients with refractory disease were excluded from their study. 7 The main reasons for these divergent results to the Freiburg group are likely differences in the cohort composition. We exclusively treated AML patients, whereas the Freiburg cohort also included 22% of patients with myelodysplastic syndrome. 8 The second difference is that one third of the patients of the Freiburg cohort received FBM conditioning followed by allogeneic HCT as front-line therapy. In contrast, all our patients except one received conventional induction or salvage therapy, and all patients classified as having active disease were refractory to chemotherapy. If this was due to the occurrence of clones with additional mutations, resulting in lower chemosensitivity, 14 remains elusive in the absence of next-generation sequencing data. In addition, differences in GvHD prophylaxis might be contributing factors as well. The Freiburg group preferentially used ciclosporine and low-dose alemtuzumab instead of ATG for in vivo T-cell depletion, whereas in our study half of the patients received tacrolimus plus ATG. Since the overall incidence of acute and chronic GvHD is very similar in both treatment cohorts, it seems unlikely that differences in the T-cell-mediated GvL effect are responsible for the differences in patients with active disease at transplant.
In summary, the FBM protocol is a well-tolerated and highly effective RIC regimen for elderly or comorbid patients with AML, in particular for those who achieve a remission at the time of transplant. Given the recent emergence of novel therapies in AML 15 we therefore encourage the treatment of patients within clinical trials so that patients might benefit from these drugs, at the earliest possible timepoint. By increasing the CR rate at the time of transplant we will also be able to further improve outcome after allogeneic HCT.
